China's anti HIV drug market ushers in the official listing of bituowei ® under Gilead Science

Since the beginning of 2020, Gilead science has been acting continuously On January 11, Gilead Science held a media conference on the listing of bituowei (bikeen Binguo) in China in Beijing Daily administration of bituowei (biconor tablets, bicrotiravir 50mg / ntrastabine) BIC / FTC / TAF, 200mg / propofol tenofovir 25mg, is the smallest triple compound single-chip preparation based on integrated enzyme chain transfer inhibitors It has been approved by China National Drug Administration (nmpa) in August 2019, and it is used to treat adults infected with human immunodeficiency virus type 1 (HIV-1) At present and in the past, there are no integrated enzyme inhibitors, Enrique Tamarin or tenofovir are resistant to the virus The spread of HIV infection in the world has become a major global public health problem HIV is an infectious retrovirus, which can infect human immune cells and cause the decrease of immune cell level It mainly attacks the most important CD4T lymphocytes in the human immune system, making the human body easy to infect a variety of diseases, and can produce malignant tumors, with a high mortality Although China's AIDS epidemic has been at a low level for a long time, the distribution of the epidemic is unbalanced, the scope of spread is wide, and the influencing factors are complex and diverse The situation of AIDS prevention and control in China is still grim, and the task is arduous In this context, it is necessary to strengthen the prevention and control of AIDS and provide a wide range of drug choices It is worth noting that anti HIV drugs are one of the fastest growing segments in the global market With the rapid development of global anti HIV drugs, the trend of AIDS treatment has changed a lot At present, the global antiviral therapy has gradually entered the era of integrated enzyme inhibitors Integrase inhibitors have the advantages of stronger antiviral effect, less side effects, less drug interactions and low drug resistance In recent years, under the background of the wide application of integrase inhibitors and new composite preparations, the market of AIDS self funded drugs has developed rapidly It can be predicted that the sales space of GTV in China will not be small After all, the number of HIV infected people in China is not small According to relevant data, from January to October 2019, 958000 people were reported to be living in China, and the drug demand of these patients continues to increase In 2018, bituowei was approved for listing by the US FDA and the European Commission respectively In the first quarter of 2019, bitovey contributed $7.93 billion to Geely's sales, exceeding the previous forecast of $6.48 billion With bitorville entering the Chinese market, Gilead is expected to usher in new opportunities in the anti HIV drug market Professor Li Taisheng, director of infection department of Peking Union Medical College Hospital, said in an interview: "at present, we have not achieved the cure of AIDS However, with the development of medicine, AIDS has become a chronic disease that can be prevented and controlled Through active and standardized treatment, infected people can achieve the same life expectancy as healthy people " Luo Yongqing, global vice president of Geely science and general manager of China, told reporters: "Geely science has been deeply involved in the field of HIV / AIDS for a long time, and has been continuously innovating and simplifying HIV treatment and prevention for many years The listing of bituowei will provide safer, more effective and simple treatment options for HIV infected people in China, and help them return to normal life " In fact, as far as Gilead is concerned, bitorville is not the first anti HIV drug Since 2000, Gilead has invested 6 billion US dollars in AIDS research and stored more than 10 products including bitorville With the expansion of demand for new HIV drugs in China, how to accelerate the entry of more relevant drugs into the Chinese market may become another springboard for Geely In August 2018, JieFuKang developed by Gilead was approved by nmpa for treatment of HIV-1 infection, becoming the first approved single tablet scheme based on TAF / FTC for treatment of HIV in China, which also marks the possibility of "multi in one" anti HIV drugs Different from the previous need to take more than one pill a day, a single pill can provide better compliance, so as to help patients adhere to the treatment At the end of last year, four innovative drugs of Gilead science were included in the national health insurance catalogue Among them, including the company's another HIV treatment single tablet drug ekorn propionate (JieFuKang) After being included in the national medical insurance catalogue, the price of the drug has been reduced from 2980 yuan / bottle / 30 capsules to 1290 yuan / bottle / 30 capsules With the implementation of the new medical insurance policy, the self paid part of patients' medical insurance is about 258-387 yuan, and the treatment cost is greatly reduced In addition, at the R & D level, as one of the global leaders in the field of HIV drug development, Gilead is also striving to achieve the direction of AIDS cure In March 2018, a pre clinical study conducted in monkeys published by the company showed that a treatment program composed of two drugs seemed to cure HIV infection in monkeys.